SUPPORTIVE CARE PROJECT

支持护理项目

• 批准号: 3916623
• 负责人: B S KRAMER
• 金额: --
• 依托单位: DIVISION OF CANCER TREATMENT
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3916623
• 关键词: blood cell count; cephalosporins; combination chemotherapy; communicable disease control; drug adverse effect; gamma globulin; human subject; human therapy evaluation; intravenous administration; leukocytes; neoplasm /cancer chemotherapy; patient care management; placebos; vancomycin

The primary goal of this group is to investigate the prophylaxis and management of infectious complications of cancer patients undergoing chemotherapy. A recently completed study was one of prophylaxis of infection in neutropenic patients with passive immunization. It was a randomized study of intravenous gammaglobulin (IVIG) versus placebo. Preliminary analysis in 75 patients randomized at the NCI and Naval Hospital, Bethesda, showed no differences between IVIG and placebo in incidence of fever, documented infection, or duration of fever. The present project is a randomized study of monotherapy (ceftazidime) versus ceftazidime plus vancomycin for the initial empiric therapy of febrile cancer patients with very low white blood counts. To date, 85 episodes have been analyzed between the two collaborating centers (NCI-NMOB and University of Florida; 20 episodes at NCI- NMOB).; Early results show a somewhat better initial response rate to combined therapy, but a very similar ultimate outcome in survival. The randomized study of ceftazidime plus/minus vancomycin is in progress. An early analysis of 85 episodes shows a higher initial response to the two drug regimen, but a similar ultimate outcome.

该小组的主要目标是研究预防措施 癌症患者感染并发症的治疗和管理 正在接受化疗。 最近完成的一项研究是其中之一 中性粒细胞减少症被动治疗患者感染的预防 免疫接种。 这是一项静脉注射的随机研究 丙种球蛋白（IVIG）与安慰剂对比。 初步分析75 在 NCI 和贝塞斯达海军医院随机分配的患者显示 IVIG 和安慰剂在发烧发生率方面没有差异， 有记录的感染或发烧持续时间。 目前的项目 是一项单一疗法（头孢他啶）与 头孢他啶加万古霉素作为初始经验性治疗 白细胞计数极低的发热性癌症患者。 迄今为止， 两人合作分析了 85 集 中心（NCI-NMOB 和佛罗里达大学；NCI-NMOB 共 20 集） NMOB）。；早期结果显示初始响应率稍好一些 联合治疗，但最终结果非常相似 生存。 头孢他啶加/减的随机研究 万古霉素正在进行中。 85集的早期分析 显示出对两种药物方案较高的初始反应，但 类似的最终结果。